← All trials
NCT00421109
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2006
- Primary completion
- Jul 1, 2007
- Completion date
- Jul 1, 2007
- First posted
- —
- Last posted
- —
- Enrollment
- 522
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- Faes Farma, S.A.Lead sponsor
- SZPITAL SPECJALISTYCZNY IM.S.Overall official - principal investigator
- Universidad Complutense de MadridOverall official - principal investigator
- Universitair Ziekenhuis GentOverall official - principal investigator
- Paris Diderot UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.